Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Bosse T, Church DN, Gilks CB. · 2020
Read Interpretation of somatic POLE mutations in endometrial carcinoma. by León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Bosse T, Church DN, Gilks CB. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7065171.txt.
Introduction
León-Castillo and co-authors tackle a sorting problem in womb cancer in The Journal of Pathology. Faults in the proofreading domain of DNA polymerase epsilon define an ultramutated subtype of endometrial carcinoma with a distinct outlook. Using that classifier in the clinic means judging which POLE mutations are truly harmful. Many observed variants had never been assessed.
The team studied 82 endometrial cancers with whole-exome sequencing from The Cancer Genome Atlas. Forty-one carried one of five known pathogenic mutations and shared a genomic fingerprint: many C-to-A changes, a very high tumour mutational burden above 100 mutations per megabase, and few insertions or deletions. They built a scoring system, the POLE-score, from those features. It reclassified 7 of 18 added tumours with domain mutations as ultramutated. Only 1 of 23 tumours with mutations outside the domain showed the pattern, so most such variants look harmless.
Catalog record
| CREATOR | León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S, Brucker SY, Carlson JW, Epstein E, Rau TT, Bosse T, Church DN, Gilks CB. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Interpretation of somatic POLE mutations in endometrial carcinoma By Alicia León‐Castillo, Heidi Britton, Melissa K McConechy, Jessica N McAlpine, Remi Nout, Stefan Kommoss, Sara Y Brucker, Joseph W Carlson, Elisabeth Epstein, Tilman T Rau, Tjalling Bosse, David N Church Published in: The Journal of Pathology DOI: 10.1002/path.5372 ABSTRACT Abstract Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) exonuclease domain define the important subtype of ultramutated tumours (‘POLE‐ultramutated’) within the novel molecular classification of endometrial carcinoma (EC). However, clinical implementation of this classifier requires systematic evaluation of the pathogenicity of POLE mutations. To address this, we examined base changes, tumour mutational burden (TMB), DNA microsatellite instability (MSI) status, POLE variant frequency, and the results from six in silico tools on 82 ECs with whole‐exome sequencing from The Cancer Genome Atlas (TCGA). Of these, 41 had one of five known pathogenic POLE exonuclease domain mutations (EDM) and showed characteristic genomic alterations: C>A substitution > 20%, T>G substitutions > 4%, C>G substitutions < 0.6%, indels < 5%, TMB > 100 mut/Mb. A scoring system to assess these alterations (POLE‐score) was developed; based on their scores, 7/18 (39%) additional tumours with EDM were classified as POLE‐ultramutated ECs, and the six POLE mutations present in these tumours were considered pathogenic. Only 1/23 (4%) tumours with non‐EDM showed these genomic alterations, indicating that a large majority of mutations outside the exonuclease domain are not pathogenic. The infrequent combination of MSI‐H with POLE EDM led us to investigate the clinical significance of this association. Tumours with pathogenic POLE EDM co‐existent with MSI‐H showed genomic alterations characteristic of POLE‐ultramutated ECs. In a pooled analysis of 3361 ECs, 13 ECs with DNA mismatch repair deficiency (MMRd)/MSI‐H and a pathogenic POLE EDM had a 5‐year recurrence‐free survival (RFS) of 92.3%, comparable to previously reported POLE‐ultramutated ECs. Additionally, 14 cases with non‐pathogenic POLE EDM and MMRd/MSI‐H had a 5‐year RFS of 76.2%, similar to MMRd/MSI‐H, POLE wild‐type ECs, suggesting that these should be categorised as MMRd, rather than POLE‐ultramutated ECs for prognostication. This work provides guidance on classification of ECs with POLE mutations, facilitating implementation of POLE testing in routine clinical care. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. INTRODUCTION Pathogenic somatic mutations in the exonuclease domain of the replicative DNA polymerase epsilon (POLE) define a subgroup of endometrial cancers (ECs) with ultramutation (frequently ≥ 100 mutations/Mb), characteristic mutation signature (COSMIC signature 10) 1, enhanced immune response 2, 3, and excellent clinical outcome 4, 5, 6, 7. ‘POLE ultramutated’ EC (POLEmut EC) has therefore been proposed as a distinct clinical entity that can be diagnosed in the presence of a pathogenic POLE exonuclease domain mutation (EDM) 8. For the five most common POLE mutations (P286R, V411L, S297F, A456P, and S459F), pathogenicity (in this sense meaning causal for tumour ultramutation) has been confirmed 4, 5, 6, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25; however, the classification of other, less frequent POLE variants is currently challenging. This is becoming an urgent problem, as POLE sequencing for molecular EC classification is rapidly entering clinical practice. Previous work has shown that ECs with a pathogenic POLE EDM typically display characteristic genomic alterations, with a high prevalence of C>A substitutions, frequently exceeding 20%; a low proportion of small insertion and deletion mutations (indels); and an extremely high tumour mutational burden (TMB; > 100 mut/Mb) 12, 26. In the pivotal 2013 EC study from The Cancer Genome Atlas (TCGA), all 17 tumours classified as ultramutated had a POLE EDM, including recurrent P286R and V411L substitutions (eight and five cases, respectively), and one case each of S297F, A456P, M444K, and L424I substitutions 7. Interestingly, 10 of 231 non‐ultramutated ECs in this study also had a POLE mutation either within or outside the exonuclease domain. Following the TCGA report, further studies have confirmed the prevalence of the five pathogenic mutations listed above and identified additional variants of uncertain pathogenicity. The parameters by which to evaluate the latter are ill defined, and thus classification of such cases is challenging, particularly in the absence of whole‐exome or whole‐genome sequencing (WES/WGS). In order to facilitate the classification of ECs in clinical practice, we aimed to develop a scoring system to estimate the pathogenicity of novel POLE mutations based on the presence or absence of genomic alterations associated with known pathogenic POLE mutations. We also sought to provide pragmatic guidelines for the interpretation of POLE variants in cases analysed by targeted POLE sequencing where such comprehensive genomic data are unavailable, being mindful that the designation of a tumour as POLE‐ultramutated EC may lead to withholding treatment, given the very favourable prognosis of this EC molecular subtype, so that a conservative approach to diagnosis is warranted. MATERIALS AND METHODS Data extraction TCGA EC cohort To analyse the base change proportions of the TCGA cohort of ECs (n = 530), we downloaded the MAF files [using Mutect for point somatic mutation call as well as small insertions and deletions (indels)] from Genome Data Commons (https://portal.gdc.cancer.gov/; accessed 27 February 2019). We used somatic called coding variants [single nucleotide substitutions (SNV), including synonymous mutations, and indels] as mutation count. To calculate tumour mutational burden (TMB), we used 38 Mb as the estimate of the exome size. Microsatellite status, as defined by the Bethesda Protocol classification 27, was obtained from the Genome Data Analysis Center (GDAC) database (https://gdac.broadinstitute.org/; accessed 30 October 2018). COSMIC signatures from all 530 TCGA ECs were obtained from mSignatureDB (http://tardis.cgu.edu.tw/msignaturedb/; accessed 22 October 2019) 28, 29. Recurrence of somatic POLE mutations in EC and pan‐cancer We searched for each somatic POLE mutation in the complete TCGA (Genome Data Commons) catalogues and COSMIC (https://cancer.sanger.ac.uk/cosmic, accessed 10 January 2019), annotating their recurrence on all cancer types (pan‐cancer) and exclusively within ECs (supplementary material, Table S1). Recurrent mutations were defined as those present in two or more cancer samples in the COSMIC and TCGA databases combined (cases present in both databases were counted only once). A mutation was considered non‐recurrent if it was found only once. In silico prediction tools To evaluate the functional status of somatic POLE mutations, we used six widely‐used in silico tools: SIFT 30, PROVEAN 31, PolyPhen‐2 32, PANTHER 33, SNAP2 34, and the meta predictor REVEL 35. SIFT is a multi‐step algorithm using sequence‐based predictive features to predict the effect of single‐nucleotide polymorphisms (SNPs) 30. PROVEAN extends this approach, additionally incorporating analysis of in‐frame insertions, deletions, and multiple substitutions 31. PolyPhen‐2 implements sequence‐based and structure‐based predictive features and compares wild‐type and mutant allele through a decision tree 32; ‘possibly damaging’ results were interpreted as benign. PANTHER is based on protein sequence, using a metric based on evolutionary conservation on direct ancestors of the organism 33; ‘possibly damaging’ and ‘probably benign’ results were interpreted as benign. SNAP2 is a neural network‐based classifier that uses sequence and structural‐based data as inputs 34. REVEL is an ensemble method based on 13 individual tools 35; scores below 0.5 were considered benign. Somatic POLE mutations reported in ECs and not detected in TCGA cases A review of the literature was undertaken, to the end of 2018, to